Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivien Wagner

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
British Journal of Haematology|May 8, 2024
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker studyXiang Zhou, Vivien Wagner, Lukas Scheller, et al.
Journal for Immunotherapy of Cancer|October 8, 2024
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myelomaJan H Frenking, Xiang Zhou, Vivien Wagner, et al.
Blood Advances|April 23, 2025
Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myelomaJan Hendrik Frenking, Xiang Zhou, Kai Rejeski, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
British Journal of Haematology|May 8, 2024
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker studyXiang Zhou, Vivien Wagner, Lukas Scheller, et al.
Journal for Immunotherapy of Cancer|October 8, 2024
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myelomaJan H Frenking, Xiang Zhou, Vivien Wagner, et al.
Blood Advances|April 23, 2025
Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myelomaJan Hendrik Frenking, Xiang Zhou, Kai Rejeski, et al.
Pageof 1